Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 March 2004, Vol. 103, No. 5, pp. 1891-1900.
Prepublished online as a Blood First Edition Paper on November 13, 2003; DOI 10.1182/blood-2002-12-3861.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2002-12-3861v1
103/5/1891    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barata, J. T.
Right arrow Articles by Cardoso, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barata, J. T.
Right arrow Articles by Cardoso, A. A.
Related Collections
Right arrow Neoplasia
Right arrow Apoptosis
Right arrow Oncogenes and Tumor Suppressors
Right arrow Signal Transduction
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

IL-7–dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL

Joao T. Barata, Vassiliki A. Boussiotis, Jose A. Yunes, Adolfo A. Ferrando, Lisa A. Moreau, J. Pedro Veiga, Stephen E. Sallan, A. Thomas Look, Lee M. Nadler, and Angelo A. Cardoso

From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Unit of Tumor Biology, Institute of Molecular Medicine, University of Lisbon Medical School, Lisbon, Portugal.

The specific targeting of critical signaling molecules may provide efficient therapies for T-cell acute lymphoblastic leukemia (T-ALL). However, target identification and drug development are limited by insufficient numbers of primary T-ALL cells and by their high rate of spontaneous apoptosis. We established a human interleukin-7 (IL-7)–dependent T-ALL cell line, TAIL7, that maintains several biologic and signaling properties of its parental leukemia cells. TAIL7 cells are pre–T-ALL cells that proliferate in response to IL-7 and IL-4. IL-7 stimulation of TAIL7 cells prevents spontaneous in vitro apoptosis and induces cell activation and cell cycle progression. The signaling events triggered by IL-7 include down-regulation of p27kip1 and hyperphosphorylation of retinoblastoma protein (Rb). Stimulation of TAIL7 cells by IL-7 leads to phosphorylation of Janus kinase 3 (JAK3), signal transducer and activator of transcription 5 (STAT5), Akt/PKB (protein kinase B), and extracellular-regulated kinase 1 and 2 (Erk1/2). Importantly, specific blockade of JAK3 by its inhibitor WHI-P131 abrogates the IL-7–mediated proliferation and survival of TAIL7 cells, suggesting that activation of JAK3 is critical for IL-7 responsiveness by these cells. Because TAIL7 cells seem to be a biologic surrogate for primary leukemia T cells, this cell line constitutes a valuable tool for the study of the signaling pathways implicated in T-ALL. Exploitation of this cell line should allow the identification of molecular targets and promote the rational design and validation of antileukemia signaling inhibitors.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
E. G. Jeong, M. S. Kim, H. K. Nam, C. K. Min, S. Lee, Y. J. Chung, N. J. Yoo, and S. H. Lee
Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers
Clin. Cancer Res., June 15, 2008; 14(12): 3716 - 3721.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. A. Wofford, H. L. Wieman, S. R. Jacobs, Y. Zhao, and J. C. Rathmell
IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival
Blood, February 15, 2008; 111(4): 2101 - 2111.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. C. R. Santos, I. Vala, C. Miguel, J. T. Barata, P. Garcao, P. Agostinho, M. Mendes, A. V. Coelho, A. Calado, C. R. Oliveira, et al.
Expression and Subcellular Localization of a Novel Nuclear Acetylcholinesterase Protein
J. Biol. Chem., August 31, 2007; 282(35): 25597 - 25603.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Acacia de Sa Pinheiro, A. Morrot, S. Chakravarty, M. Overstreet, J. H. Bream, P. M. Irusta, and F. Zavala
IL-4 induces a wide-spectrum intracellular signaling cascade in CD8+ T cells
J. Leukoc. Biol., April 1, 2007; 81(4): 1102 - 1110.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
J. T. Barata, A. Silva, J. G. Brandao, L. M. Nadler, A. A. Cardoso, and V. A. Boussiotis
Activation of PI3K Is Indispensable for Interleukin 7-mediated Viability, Proliferation, Glucose Use, and Growth of T Cell Acute Lymphoblastic Leukemia Cells
J. Exp. Med., September 7, 2004; 200(5): 659 - 669.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020